GLP1 – Semi | GLP-1 Receptor Agonist Research Peptide
$ 110.00 – $ 190.00Price range: $ 110.00 through $ 190.00 - or subscribe
GLP1 – Semi is a 31-amino-acid acylated GLP-1 receptor agonist peptide, studied for its role in GLP-1 receptor pathway signaling, glucose homeostasis regulation, and adipose tissue response in research models. Supplied as a lyophilized vial for in-vitro laboratory research use only.
Research-grade specs
- Sequence length: 31 amino acids
- Class: GLP-1 receptor agonist (acylated)
- Half-life: ~7 days
Studied applications
- Glucose homeostasis and insulin sensitivity research
- Body-composition and adipose tissue studies
- Cardiovascular outcome research (SELECT trial framework)
- GLP-1 receptor comparison studies with dual and triple agonist research compounds
Quality & trust
- ≥99% HPLC purity, third-party tested
- Mass spectrometry identity confirmation
- LAL endotoxin testing on every batch
- Batch-specific Certificate of Analysis included
- USA same-day shipping (orders before 2pm CT M-F)
Related research: Tirzepatide · Retatrutide · Replacement supplier guide
Research literature
Semaglutide has been the subject of 4,625 peer-reviewed publications indexed in PubMed. Selected recent literature for research reference:
- Johansson E et al. (2026). Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial. J Med Econ. PMID: 42012820
- Chikatimalla R et al. (2026). GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers. Ann Med. PMID: 41999297
- Guldhammer A et al. (2026). A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark – ‘she is probably on the meds’. Scand J Prim Health Care. PMID: 41838446
- Kanumilli N et al. (2026). Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK. J Med Econ. PMID: 41771166
- Wang Y et al. (2026). Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis. Ren Fail. PMID: 41644273
References are provided for research reference only. Inclusion of literature does not constitute a recommendation, endorsement, or claim for any specific use of LiveWell Peptides products. Products are sold for laboratory and research use only and are not intended for human consumption, injection, topical application, or any other administration to the human body.
| Quantity | Price | Discount |
|---|---|---|
| 3-5 | $ 105.60 | 4% |
| 6-8 | $ 101.20 | 8% |
| 10-15 | $ 97.90 | 11% |
| 16+ | $ 110.00 | $ 0.00 |
Add $ 200.00 to cart and get free shipping!
Description
GLP-1 (GLP1 – Semi) Research Peptide
GLP-1 (Glucagon-Like Peptide-1) receptor agonist peptide is a highly studied compound in metabolic research, primarily focusing on blood sugar regulation, GLP-1 receptor pathway signaling, and metabolic mechanism studies. Supplied as a lyophilized vial, GLP1 – Semi is designed for in-vitro laboratory research, providing researchers with a reliable tool to study GLP-1 receptor pathways and metabolic mechanisms. This laboratory-grade peptide is available in 5 mg and 10 mg vial sizes, suitable for controlled experimental assays and biochemical studies.
Used widely in metabolic disorder research, GLP-1 peptides help scientists investigate cellular responses, hormone signaling, and receptor interactions related to glucose metabolism and energy balance. Please note, this product is strictly for research purposes only and is not intended for human or veterinary use. Researchers are advised to handle the peptide under proper laboratory safety protocols and follow all institutional guidelines for storage and disposal.
LiveWell Peptides ensures that GLP1 – Semi is high-purity, lyophilized, and tested for consistency, making it an ideal choice for metabolic and receptor pathway studies in the USA. This product enables precise in-vitro experimentation, supporting advancements in metabolic pathway research and receptor interaction studies
Reference Link: Click Here
